Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)

Official title

Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Overview

The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).

Interventions

• Device VDyne Transcatheter Tricuspid Valve Replacement System
  The study investigational device is the VDyne Transcatheter Tricuspid Valve Replacement System which consists of a bioprosthetic implantable tricuspid valve, the VDyne Delivery System, Drop Tether, accessories that facilitate the placement of the valve and the VDyne Retrieval System. The VDyne Valve is deployed by transfemoral implantation within the native tricuspid valve and is implanted under fluoroscopic and transesophageal echocardiography (TEE) guidance, while the heart remains beating, wi

Primary outcome measures

• The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC). [Time frame: Implant to 30 days post-procedure]
• Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs [Time frame: Baseline to 1 month after implant]
• Changes in symptom status (NYHA class) [Time frame: Baseline to 1 month after implant]
• Changes in functional capacity (6-minute walk test) [Time frame: Baseline to 1 month after implant]
• Changes in in quality of life (KCCQ score) [Time frame: Baseline to 1 month after implant]

Secondary outcome measures (7)

• The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC). [Time frame: 30 days post-procedure to 1 year]
• Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs [Time frame: 1 month after implant to 1 year post-implant]
• Changes in right ventricle as measured by core lab [Time frame: 1 month after implant to 1 year post-implant]
• Rate of heart failure hospitalization [Time frame: 1 month after implant to 1 year post-implant]
• Changes in symptom status (NYHA class) [Time frame: 1 month after implant to 1 year post-implant]
• Changes in functional capacity (6-minute walk test) [Time frame: 1 month after implant to 1 year post-implant]
• Changes in in quality of life (KCCQ score). [Time frame: 1 month after implant to 1 year post-implant]

Eligibility criteria

Inclusion criteria

• Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
• NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
• Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
• index procedure, including a diuretic.
• Heart Team determines patient is a recommended candidate for the VDyne System.
• Age >18 years at time of index procedure.
• Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.

Exclusion criteria

• Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs, Sponsor or Clinical Screening Committee (CSC)
• Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
• Hypersensitivity to nickel or titanium
• Left Ventricular Ejection Fraction (LVEF) <30%.
• Severe RV dysfunction.
• Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
• Sepsis including active infective endocarditis (IE) (within last 6 months).
• Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
• Severe tricuspid annular or leaflets calcification.
• Systolic pulmonary hypertension with systolic pulmonary artery pressure >70 mmHg.
• History or rheumatic fever
• Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
• Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
• Unresolved severe symptomatic carotid stenosis (> 70% by ultrasound).
• Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
• Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
• Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
• Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
• Significant valvular heart disease requiring intervention other than the tricuspid valve.
• Known significant intracardiac shunt (e.g. septal defect)
• Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
• Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
• Acute myocardial infarction (AMI) within 30 days.
• Significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on dialysis.
• End-stage liver disease (MELD > 11 / CHILD class C).
• Bleeding requiring transfusion within prior 30 days.
• Coagulopathy or other clotting disorder that cannot be medically managed.
• Chronic immunosuppression or other condition that could impair healing response.
• Any of the following: leukopenia, chronic anemia (Hgb < 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
• Unwilling to receive blood products.
• Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
• Life expectancy less than 12 months due to non-cardiac comorbidities.
• Treatment is not expected to provide benefit (futile).
• Current IV Drug user (must be free drug abuse for > 1 year).
• Pregnant, lactating or planning pregnancy within next 12 months.
• Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
• Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
• Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
• Patient unable or unwilling to comply with study required testing and follow-up visits

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 10 centers

• Cedars-Sinai Medical Center — Los Angeles
• Henry Ford Hospital — Detriot
• Minneapolis Heart Institute Foundation — Minneapolis
• Mayo Clinic - Rochester — Rochester
• Columbia University Medical Center/NYPH — New York
• Montefiore Medical Center — The Bronx
• The Christ Hospital — Cincinnati
• Oregon Health and Science Unversity — Portland
• … and 2 more centers

Canada · 1 center

• Québec-Université Laval (IUCPQ-ULaval) — Québec

Identifiers

NCT: NCT05848284 · TPR0037-P

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗